急性髓系白血病微小残留病监测：二代测序应该成为临床常规吗？

Minimal residual disease monitoring in acute myeloid leukemia： will next generation sequencing be used in clinical routine？

急性髓系白血病（AML）是一类具有很强异质性的恶性血液病.精准的预后分层是实施个体化治疗的前提,系列随访监测微小残留病（MRD）是当前重要的预后分层指标.新近发展起来的二代测序（NGS）技术已逐渐被用于临床常规初诊AML患者基因突变的筛查,该技术自身特点显示其可以用于MRD监测,已有一些证据初步显示了其临床意义,因而NGS是一种很有潜力的临床常规MRD监测方式.然而,尚有一些关键问题有待回答.

Acute myeloid leukemia （AML） is a highly heterogeneous hematologic malignancy. The precise prognostic stratification is the premise of the individualized treatment. The serial monitoring of minimal residual disease （MRD） has become the important stratification marker at present. The newly developed next generation sequencing （NGS） technique has been gradually used in AML patients for gene mutation screen in clinical routine. The characteristics of NGS technique implies its availability for MDS monitoring, and the preliminary data on its application in MRD monitoring have demonstrated its clinical significance. Therefore, NGS technique has the great potential for MRD monitoring in clinical practice. However, some key points remain to be solved.